Brookfield Infrastructure Partners LP vs Medtronic PLC — how do they compare? Brookfield Infrastructure Partners LP trades at $38.84 (market cap $17.38B), while Medtronic PLC trades at $81.26 (market cap $101.51B). The key difference: Medtronic PLC is far larger — about 5.8× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.77%). Which is the better fit depends on your goals.
| BIP | MDT | |
|---|---|---|
Market Cap | $17.38B | $101.51B |
Sector | Industrials | Health |
52-Week High | $40.08 | $105.35 |
52-Week Low | $29.81 | $73.75 |
Enterprise Value | $79.06B | $120.25B |
Dividend Yield | 4.77% | 3.63% |
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.
BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.
Medtronic (MDT) trades at $83.57, down 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $97.50. The company reported strong revenue growth to $33.54B in 2025, with net income of $4.66B and a net margin of 13.2%. Recent acquisitions, such as Scientia Vascular (PRNewsWire, 2026-06-12), and consistent earnings beats highlight operational strength and strategic expansion in medical technology.
MDT presents a compelling investment case with a 3.5% dividend yield and undervalued metrics relative to growth, but faces risks from rising debt levels and margin pressures. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on fiscal 2027 guidance and macroeconomic headwinds impacting healthcare spending.
Trailing returns across standard periods
Latest headlines on both assets
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →